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Abstract
The identification of new biomarkers is of high interest for the prediction of the disease course and also for the identification
of pathomechanisms in multiple sclerosis (MS). To specify markers of the chronic disease phase, we performed proteome
profiling during the later phase of myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalo-
myelitis (MOG-EAE, day 35 after immunization) as a model disease mimicking many aspects of secondary progressive MS. In
comparison to healthy controls, high resolution 2 dimensional gel electrophoresis revealed a number of regulated proteins,
among them glial fibrilary acidic protein (GFAP). Phase specific up-regulation of GFAP in chronic EAE was confirmed by
western blotting and immunohistochemistry. Protein levels of GFAP were also increased in the cerebrospinal fluid of MS
patients with specificity for the secondary progressive disease phase. In a next step, proteome profiling of an EAE model
with enhanced degenerative mechanisms revealed regulation of alpha-internexin, syntaxin binding protein 1, annexin V and
glutamate decarboxylase in the ciliary neurotrophic factor (CNTF) knockout mouse. The identification of these proteins
implicate an increased apoptosis and enhanced axonal disintegration and correlate well the described pattern of tissue
injury in CNTF 2/2 mice which involve oligodendrocyte (OL) apoptosis and axonal injury. In summary, our findings
underscore the value of proteome analyses as screening method for stage specific biomarkers and for the identification of
new culprits for tissue damage in chronic autoimmune demyelination.
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Introduction
The recent years faced substantial advance in early and at the
same time accurate diagnosis of multiple sclerosis (MS, [1,2]). Yet,
the need for reliable markers of disease prognosis is still unmet.
While magnetic resonance imaging (MRI) has been proven useful
in the early disease phases, the present routine MRI protocols are
only of limited value for the prediction of long term prognosis of
MS [3]. Thus, stage specific prognostic biomarkers are of high
interest for accurate patient counseling. Still, evidence on the
reliability of some present-day biomarkers is conflicting (for review
see [4,5]). While first data pointed at the value of serum anti-
myelin antibodies as predictor of clinically definite MS, this could
not be reproduced in follow-up studies [6,7]. Some studies
identified the intrathecal synthesis of oligoclonal IgM as predictor
of an aggressive course of MS [8,9], while it does not predict an
early diagnosis [10]. Screening for polymorphisms associated with
disease progression led to the identification of variations in the
gene of the signaling molecule PD1 as genetic modifier [11] and a
genome wide association studies identified the IL2RA and IL7RA
as risk factors for MS [12]. For further systematic identification of
candidate genes, expression profiling in MS may prove useful
[13–15]. In the recent years, a vast number of gene array studies in
MS were carried out and mainly allowed insights in therapeutic
mechanisms or were employed to determine the response to
immunomodulatory treatment (for example [16]). In contrast, only
few studies addressed the systematic identification of regulated
proteins so far [17]. In fact, protein profiling mainly focused on the
screening for autoantibodies in autoimmune diseases [18].
Best candidates for prognosis relevant proteins may be those
directly derived from the central nervous system (CNS) as target
tissue of the immune reaction. Since the ready availability of these
proteins in MS may prove difficult, it seems worthwhile to first
investigate their regulation in experimental models. In particular,
myelin oligodendrocyte glycoprotein induced experimental auto-
immune encephalomyelitis (MOG-EAE) mimics many features of
relapsing-progressive or secondary progressive MS [19,20].
Indeed, gene expression profiling revealed differential gene
regulation in the CNS as well as the microvascular compartment
of EAE diseased mice [21,22]. Recently, the differential expression
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proteomic analysis using isobaric tags [23] and in correlation to
immunohistochemistry [24]. While all these studies showed the
technical feasibility of genomic or proteomic analyses in
autoimmune demyelination, a candidate marker protein which
could be directly transferred from the experimental screening to
the clinical situation has not been described so far.
Here we employed proteome profiling of MOG-EAE and the
ciliary neurotrophic factor knockout mouse (CNTF 2/2 mouse)
as model with enhanced tissue injury including axonal degener-
ation and oligodendrocyte (OL) apoptosis to screen for disease
regulated proteins which could serve as candidate biomarkers in
MS patients.
Materials and Methods
Animals
C57BL/6 mice were purchased from Harlan (Borchen,
Germany) and kept at the animal care facilities of the Institute
for MS Research, University of Go ¨ttingen, Germany. CNTF 2/2
mice were backcrossed to the C57BL/6 background for more
than 14 generations and bred at the in-house animal care facilities.
These mice were characterized in detail in previous studies and
display an increased OL apoptosis and enhanced axonal
degeneration over the later phases of MOG-EAE [25,26]. All
animal experiments were performed in accordance with the Lower
Saxony State regulations for animal welfare.
Induction and clinical evaluation of active MOG-EAE
For active induction of EAE, mice received a s.c. injection at
flanks and tail base of 200 mg MOG 35–55 peptide (Charite ´,
Berlin, Germany) in PBS emulsified in an equal volume of CFA
containing Mycobacterium tuberculosis H37RA (Difco, Detroit
MI, USA) at a final concentration of 1 mg/ml. Two injections of
pertussis toxin (List Biochemicals, Campbell, CA, USA, 400 ng
per mouse i.p.) were given at the time of immunization and
48 hours later. Animals were weighed and scored for clinical signs
of disease on a daily basis using a clinical score as described
previously [25].
Tissue processing
On day 35 or 37 after immunization (p.i.), mice were
anesthetized with Ketanest (Inresa, Freiburg, Germany) and
Rompun (Bayer, Leverkusen, Germany), transcardially perfused
with saline and spinal cords were carefully removed. For
histochemical analyses perfusion with saline was followed by a
solution of 4% paraformaldehyde (PFA) and spinal cord tissue was
postfixed in the same fixative for two hours. Subsequently, axial
paraffin sections (3 mm) or, after resin embedding, semi-thin
sections (0.5 mm) were obtained.
Immunohistochemistry and histopathology
Histopathological evaluation included anti-GFAP immunohis-
tochemistry (rat anti-GFAP, dilution 1:1000, DAKO) and
toluidine blue staining of semi-thin sections. For GFAP staining,
the primary antibody was incubated overnight at 4uC. After
washing, sections were incubated with the appropriate secondary
antibody (Invitrogen Hamburg, Germany) at a dilution of 1:100)
and developed using diaminobenzidine (DAB) as chromogenic
substrate. Specificity of staining was confirmed by omitting
the primary antibody. Sections were mounted with Entellan
(Sigma) and analyzed by light microscopy (Olympus, Hamburg,
Germany).
Two-dimensional difference gel electrophoresis (2D
DIGE)
First-dimension isoelectric focusing was performed with immo-
bilized pH 3 to 10 nonlinear gradient gels (24-cm Immobiline dry
strips pH 3–10 NL; GE Healthcare). IPG strips were rehydrated
for 24 h in 7 M urea22 M thiourea24% CHAPS21% dithio-
threitol (DTT)20.4% IPG buffer pH 3–10 NL20.002% bromo-
phenol blue. Whole spinal cord samples were dissolved in 3
volumes of ice-cold acetone and precipitated overnight at 220uC.
Proteins were pelleted, air dried for 1 h, and lysed in 7 M
urea22 M thiourea24% CHAPS-30 mM Tris-HCl (pH 8.1) by
rocking for 1 h at ambient temperature for subsequent labeling.
Insoluble material was removed by centrifugation. The proteins
were labeled as specified by the manufacturer with fluorescent
dyes specifically developed for the two-dimensional 2D difference
gel electrophoresis system (2D-DIGE) (CyDyes Cy2, Cy3, and Cy5
[GE Healthcare]). For the mixed internal standard, aliquots of
each individual sample included in the experiment were pooled
and labeled with Cy2 in the same dye-to-sample ratio. After
30 min incubation at 8uC in the dark, the labeling reaction was
abrogated by adding 20 nmol lysine and incubating for further
10 min. The labeled samples were combined and diluted 1.33 fold
by a stock solution containing 7 M urea, 2 M thiourea, 4%
CHAPS, 4% IPG-buffer 4–7, 4% DTT w/v for subsequent IEF.
Labeled samples were cup-loaded near the anodic end, and
isoelectric focusing was carried out for a total of 56.000 Vh (1 h
150 V, ramp for 3 h to 300 V, ramp for 6 h to 1000 V, ramp for
3 h to 8000 V, hold at 8000 V for 4:40 h). After focusing, the
strips were equilibrated for two 25-min intervals in 6 M urea-
125 mM Tris-HCl (pH 7.85)23% SDS-20 (vol/vol) glycerol; 1%
DTT was added for the first equilibrium step, and 4.2%
iodoacetamide (IAA) was added for the second equilibrium step.
Second dimension SDS-PAGE was performed with homogeneous
11% polyacrylamide gels (254 by 200 mm) by the method of
Tastet et al. [27] with 150 g Tris/0.6 M HCl as gel buffer and
taurine instead of glycine as buffering ion in the running buffer at
4 W/gel overnight at 25uC. The fluorescence signals of the three
differently CyDye-labeled protein samples were imaged using a
laser scanner recording band pass filtered emission wavelengths of
520 nm (Cy2); 580 nm (Cy3) and 670 nm (Cy5) respectively
(Typhoon 9400 GE Healthcare). For comparison of wild type mice
with or without EAE a set of 2 gels were run in a dye swap
manner. For the comparison of CNTF knockout mice with wild-
type controls, a set of 6 gels were run, with a total of 6 individual
samples per group. The gels were analyzed with the different
software modules of the DeCyder differential analysis software
(GE Healthcare). Proteins were post-stained with colloidal
Coomassie. Spots of interest were excised manually as described
previously [28] and subjected to mass spectrometric protein
identification
Protein identification
Proteins were identified by two approaches as described recently
[29,30]. Briefly, an automated platform was used to digest the
proteins in-gel with trypsin and to prepare the proteolytic peptides
for MALDI-TOF-MS. For each sample, a peptide mass
fingerprint (PMF) spectrum and fragment ion spectra of up to
four selected precursor ions were acquired within the same
automated analysis loop using an Ultraflex I mass spectrometer
(Bruker Daltonics). Data base searches were performed with the
Mascot Software 2.0 (Matrix Science) licensed in-house. Only
proteins represented by at least one peptide sequence above
significance threshold in combination with the presence of at least
Proteomics in EAE
PLoS ONE | www.plosone.org 2 October 2009 | Volume 4 | Issue 10 | e7624four peptide masses assigned in the PMF were considered as
identified (for detailed reference see [31,32]).
Protein Sequence Analysis by LC-MS/MS
To confirm the data obtained from mass finger print analysis,
some samples were subjected to peptide sequence analysis. The
peptide sequencing analysis was performed as described elsewhere
[29,33]. Briefly, extracted peptides were dissolved in 0.1% formic
acid (FA) and one microliter of sample was introduced using a
CapLC autosampler (Waters, Manchester, UK) onto a m-
precolumn Cartridge (C18 pepMap, 300 mm65 mm; 5 mm
particle size, LC Packings Idstein, Germany) and further separated
through a C18 pepMap100 nano Series (75 mm615 cm; 3 mm
particle size) analytical column (LC Packings Idstein, Germany).
The mobile phase consisted of solution A (5% ACN in 0.1% FA)
and solution B (95% ACN in 0.1% FA). The total sample running
time was set to 60 min. Peptide sequencing was performed on a Q-
TOF Ultima Global (Waters) mass spectrometer equipped with a
nanoflow ESI Z-spray source in the positive ion mode. Multiple
charged peptide parent ions were automatically marked and
selected in the quadrupole and fragmented in the hexapole
collision cell, and their fragment patterns were analyzed by time-
of-flight. Data were acquired using MassLynx (v 4.0) software
(Waters) on a Windows NT PC, and were further processed on a
Protein-Lynx-Global-Server (PLGS) v. 2.1. (Waters, Manchester,
UK). The raw data files were deconvoluted and deisotoped using
the Max Ent lite algorithm (Waters). A PLGS module was used to
generate Mascot-searchable *.pkl files. The *.pkl processed data
were searched against a NCBI database via a Mascot search
engine using a peptide mass and MS/MS tolerance of 0.5 Da. The
search criteria were set with one missed cleavage by trypsin
allowed and protein modifications set to methionine oxidation and
carbamidomethylcysteine when appropriate.
GFAP Western Blotting
Separation of proteins (homogenates 40 mg/lane), blotting,
detection, and quantification of the signals were performed as
described [34]. Blots were incubated with rabbit anti-GFAP
antibody (DAKO, 1:7500 in 3% MMP/TBST) followed by
incubation with a biotylinated anti-rabbit antibody (Vector,
1:10000). The signals were standardized relative to the amount
of GFAP in wild-type spinal cord. A representative experiment of
two independent analyses is shown (n=3 for each genotype).
Patients
All analyses were approved by the local ethics committee of the
University Ulm. Patients were admitted to the Department of
Neurology, University Ulm in 2007. CSF-samples of 22 patients
were collected within the scope of the routine work-up and were
stored at 280uC until the carrying out of the laboratory
experiments.
The MS patient group consists of 14 adult patients (age between
19 and 55) who were diagnosed with MS according to the
McDonald criteria. Additionally, all patients were classified
according to the EDSS score and underwent magnetic resonance
imaging (MRI) of the neurocranium and spine. All investigated
CSF-samples of MS patients showed oligoclonal bands. At the
time of the lumbar puncture, the relapsing remitting MS patients
did not receive any disease modifying treatment. In contrast, two
patients suffering from secondary-chronic progressive MS received
interferon-b therapy.
In the control group, eight adult patients (age range between 18
and 44 years) underwent lumbar puncture as a part of the
neurologic differential diagnosis. None of these patients presented
a chronic inflammatory neurologic disease. The CSF evaluations
of these patients were assessed as normal findings. On the
occasion, no oligoclonal bands were detected. Both, the cell count
and the protein levels were in normal ranges.
Measurement of the GFAP concentrations in CSF samples
Determination of GFAP concentration in the individual samples
was performed according to the manufacturer protocol using an
enzyme-linked immunoabsorbent assay (ELISA; BioVendor). The
analytical limit of detection was 0.033 ng/ml. The sensitivity of
the used assay takes the dilution of the samples into consideration
and is calculated according to the formula: Assay sensitivity =
Analytical limit of detection x sample dilution =0.033 ng/
ml63=0.1 ng/ml.
Statistical Analysis
The comparison of the GFAP concentrations between the
different subgroups was based on nonparametric rank tests (for two
groups, Wilcoxon Mann-Whitney-U-test; for more than two
groups, the Friedman 2-way ANOVA by ranks). Differences were
considered significant at *p,0.05, and ** p,0.01.
Results
Proteome profiling in the chronic phase of murine MOG-
EAE
To identify markers of disease progression in chronic progres-
sive autoimmune demyelination, we investigated the regulation of
proteins by proteome profiling of the early chronic phase (day 35
p.i.) of MOG-EAE in the C57BL/6 mouse as a model disease.
2DIGE of spinal cord tissue revealed a number of regulated
proteins, among them the astrocyte marker glial fibrillary acidic
protein (GFAP, see Fig. 1), but also transferrin precusor,
calreticulin precursor and protein disulfide isomerase precursor
(Table 1).
Confirmation of GFAP up-regulation in the spinal cord of
chronic MOG-EAE
We aimed to confirm GFAP as a regulated marker protein in
murine MOG-EAE. To that end, protein levels of GFAP were
investigated by Western Blot (Fig. 2) over the course of the disease
at an early chronic (day 35 p.i.) and late chronic time point of
MOG-EAE (day 60 p.i.). Quantification of protein levels revealed
a significant, up to 2 fold increase of GFAP protein levels in the
later disease phases (Fig. 2B).
These data were correlated with GFAP immunohistochemistry
which revealed thin GFAP positive astrocytes without gliosis in
naive control mice while over the course of MOG-EAE, astrocytes
displayed strongly GFAP positive stellar shaped cell bodies
accompanied by a diffuse GFAP staining indicating fibrillary
gliosis (Fig. 2C).
Regulation of GFAP in the CSF of MS patients
To prove the relevance of GFAP as a regulated protein in
human autoimmune demyelination, we investigated this candidate
marker in the CSF of MS patients. There was a significant increase
of GFAP protein in patients suffering from secondary progressive
MS, whereas patient with a relapsing remitting disease course
displayed levels similar to healthy controls (see Table 2 for baseline
characteristics of patients and Fig. 3A,B for results). The GFAP
levels for secondary chronic progressive MS patients were between
1.7 ng/ml to 2.4 ng/ml (median 2.05 ng/ml) and in the relapsing
remitting group between 0.587 ng/ml to 1.275 pg/ml (median
Proteomics in EAE
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between 0.507 ng/ml to 1.595 ng/ml (median: 0.961 ng/ml).
Proteome profiling in a disease model with enhanced
tissue damage
Finally, we were interested to investigate marker proteins not
only correlating with the disease stage, but also patterns of tissue
damage. Thus, we investigated the regulation of proteins after
induction of MOG-EAE in the model of the CNTF 2/2 mouse,
a well characterized paradigm with enhanced OL apoptosis and
axon damage on days 28 and 56 p.i. after immunization [25].
Proteome profiling of the early chronic phase of MOG-EAE in
CNTF 2/2 versus wild-type mice was performed on day 37 p.i.
At this time, CNTF 2/2 mice displayed a more pronounced
motor impairment as compared to matched controls (mean clinical
score 6 SEM: 6.160.6 in CNTF 2/2 mice vs. 4.660.7 in wild-
type mice, p=0.02). Proteomic analyses revealed a number of
significantly regulated proteins (Table 3) as proven by analysing
groups of individual mice. While this approach did not reveal the
regulation of the stage-specific marker GFAP as associated with
enhanced tissue damage, the analysis disclosed an increase in the
axonal structure proteins alpha-internexin as part of the
neurofilament apparatus and also syntaxin binding protein 1 in
CNTF 2/2 mice (see Fig. 4 for gel and Fig. 5 for quantitative
analysis). Moreover, CNTF 2/2 mice displayed an increase in
annexin V as apoptosis marker, but a decrease in glutamate
decarboxylase which is involved in glutamate metabolism and and
also altered in demyelinated lesions [35]. Finally, we identified an
increase in RAP1 (GTP-GDP dissociation stimulator 1) and a
decrease of enolase-phosphatase 1 in CNTF 2/2 mice (see
table 3) as proteins of the cellular metabolism with a so far
miscellaneous function in EAE. These changes were not found in
first analyses comparing naı ¨ve CNTF 2/2 and wild-type mice.
In summary, the regulated proteins point at an increased
apoptosis and glutamate mediated excitotoxicity along with
changes in the axonal neurofilament apparatus in EAE diseased
CNTF 2/2 mice. These observations correlate well with the
destructive pathology and also OL apoptosis in EAE lesions of
CNTF deficient mice on day 35 p.i. (Fig. 6) which were already
described on days 28 and 56 p.i. in earlier studies [25].
Discussion
Here we performed proteome profiling of murine MOG-EAE
as a model of secondary progressive MS.
First, our data reveal an up-regulation of GFAP in the spinal
cord in the chronic disease phase of MOG-EAE. These findings
could be transferred from the experimental model to the clinical
setting with an increase of GFAP also in the CSF of secondary
progressive MS patients. An increase of GFAP expression during
autoimmune demyelination was already shown in different models
of EAE [36–38] with acute as well as relapsing remitting disease
courses. Our data extend these previous findings also to the
chronic phase of MOG-EAE. The up-regulation of GFAP in the
later phase of the disease implies a role of astroglia during
chronicity of autoimmune demyelination. In contrast, some
previous studies also point towards a role of glial cells in the
regulation of the target tissue response to an inflammatory insult
[39]. Here, studies in the model of GFAP knockout mice are
somewhat hampered by a complex phenotype with impaired white
matter architecture [40].
Moreover, previous data indicate that assessment of GFAP in
the CSF of MS patients with a newly developed ELISA may be
Table 1.
Spot No. Protein name Swiss-Prot accession MW [Da] pI coverage [%] score Peptides
1 Glial fibrillary acidic protein Q80VX6 49870 5.27 45 731 22
2 Protein disulfide-isomerase
precursor
P09103 57108 4.79 16 134 7
3 Protein disulfide-isomerase A3
precursor
P27773 56643 5.88 26 291 14
4 Serum albumin precursor P07724 68648 5.75 45 760 21
5 Serotransferrin precursor Q63915 76674 6.94 22 284 15
doi:10.1371/journal.pone.0007624.t001
Figure 1. Proteome analysis of chronic MOG-EAE. 2D-DIGE gel of
brain proteins from wild type mice with EAE, labeled with Cy3 (shown in
red) versus healthy control (without EAE) labeled with Cy5 (shown in
green). Images of gel region containing the glial fibrillary acidic protein
(GFAP; identified by Mass Spectrometry) is shown in detail for the
respective CyDye. IS = Internal Standard (Mixture of Samples). Proteins
were separated on 24 cm IPG Strip pH 3–10 non-linear. CRNP=
Calreticulin Precursor; PDI=Protein Disulfid Isomerase Precursor.
doi:10.1371/journal.pone.0007624.g001
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(day 35 p.i.) and late chronic phase of the disease (day 60 p.i.). Each lane represents the GFAP expression of one single mouse, b-actin serves as a
loading control. (B) Quantification of optical densities of the GFAP labeling as shown in figure 2A. There was a clear increase in GFAP expression over
the course of MOG-EAE (p,0.05 on day 60 p.i.). (C) Immunohistochemistry for GFAP in naı ¨ve C57BL/6 mice without EAE (left) and on day 35 p.i.
(middle) and 60 p.i. (right). Representative images from spinal cord cross sections are shown, arrows indicate GFAP positive astrocytes which appear
elongated in naı ¨ve mice and swollen in the chronic phases of MOG-EAE. Bar represents 20 mm.
doi:10.1371/journal.pone.0007624.g002
Table 2.
Disease Course Number Age (range) Gender EDSS-Score GFAP (ng/ml; range)
Secondary-chronic progressive MS n=4 25–55 3 F, 1 M 5.0–8.5 2.05 (1.7–2.4)
Relapsing-remitting MS n=10 19–55 6 F, 4 M 2.0–3.5 0.815 (0.587–1.275)
Non neurological disease n=8 18–44 4 F, 4 M n.a. 0.961 (0.507–1.595)
doi:10.1371/journal.pone.0007624.t002
Proteomics in EAE
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CSF of MS patients, in particular in secondary progressive MS
patients which is well in line with previous observations [37,38]
and adds GFAP to other markers like neurofilament or nitric oxide
metabolites that were also shown to correlate with disability or
disease progression [42,43].
The similar findings on the regulation of GFAP in spinal cord
tissue of MOG-EAE and the CSF from secondary progressive MS
Figure 3. Detection of GFAP in CSF samples of secondary progressive MS patients. (A) Boxplot analysis of a group of unselected MS
patients in comparison to control patients without neurological disease. GFAP levels in the CSF are increased in the multiple sclerosis (MS) group
(p,0.05). (B) Boxplot analysis comparing secondary progressive MS (SP-MS) patients, relapsing remitting MS (RR-MS) patients and controls. GFAP
levels in the CSF are exclusively increased in the secondary progressive MS group.
doi:10.1371/journal.pone.0007624.g003
Table 3.
Spot No. Protein name
Swiss-Prot
accession MW [kDa] pI
PMF
coverage [%]
PMF
score
a Peptide sequenced
MS/MS ion
score
b
I Annexin A5 P48036 35.8 4.8 23 67 GTVTDFPGFDGR 27
GLGTDEDSILNLLTSR 25
FITIFGTR 6
II RAP1, GTP-GDP dissociation
stimulator 1
NCBI:
gi|148680137
c
61.1 5.4 59 177 DLASAQLVQILHR 73
HVEDGNVTVQHAALSALR 58
III Alpha-internexin P46660 55.9 5.2 50 242 HSAEVAGYQDSIGQLESDLR 139
FSTGGLSISGLNPLPNPSYLLPPR 99
IV Syntaxin-binding protein 1 O08599 67.9 6.5 26 82 DNALLAQLIQDK 14
LAEQIATLCATLK 14
VI Enolase-phosphatase E1 Q8BGB7 28.7 4.8 21 32 AEFFADVVPAVR 44
LLFGHSTEGDILELIDGHFDTK 6
V Glutamate dehydrogenase
1, mitochondrial precursor
P26443 61.6 8.1 48 162 HGGTIPVVPTAEFQDR 54
IIKPCNHVLSLSFPIR 50
a)Mascot protein score obtained for the peptide mass fingerprint (PMF). The significance threshold was 54.
b)Mascot MS/MS ion scores obtained for the individual peptides sequenced. The significance threshold for identity was 22–28 depending on how many peptides fell
within the mass tolerance window about the precursor mass. Only the top ranking peptides matching a query for the first time (‘‘bold red hits’’) are reported.
c)Data were searched against the NCBI data base as the search against the Swiss-Prot database did not reveal any identification.
doi:10.1371/journal.pone.0007624.t003
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expression in the CNS from the animal model and the CSF
compartment in MS patients. Moreover, these data also serve as a
proof of principle revealing that proteomics can be a valuable tool
for translational medicine. Proteome analysis of murine EAE
models may allow the identification of candidate biomarkers
which can then be transferred to the respective MS stages in
clinical practice. Indeed, CNS derived proteins may not only serve
as bulk markers of the disease [44], but could also show stage
specificity thus helping to predict disease prognosis.
Second, proteome analysis of MOG-EAE in CNTF 2/2 mice
reveals a regulation of proteins involved in apoptosis (annexin V)
and also regulation of excitoxicity (glutamate decarboxylase).
Moreover, CNTF 2/2 mice displayed an increase in axonal
structure proteins like alpha-internexin indicating an enhanced
axonal disintegration. These findings correlate well with the
previously described histopathological pattern in CNTF 2/2
mice which includes an increased OL apoptosis and also an
enhanced axonal injury. In the light of the decreased expression of
glutamate decarboxylase in CNTF 2/2 mice and the role of
glutamate excitotoxicity as a mechanism for axonal damage and
OL death in autoimmune demyelination [45], it is tempting to
speculate that a decreased glutamate metabolism may lead to
enhanced excitotoxicity which then precipitates the pronounced
tissue damage in this model.
Other candidate markers which are possibly linked to
pathomechanisms of disease and were identified in specimen of
MS patients include hypoxia associated factors [46] for ischemic
Figure 4. Proteome analysis of CNTF knockout mice. 2D-DIGE gel
of spinal cord proteins from CNTF knock-out mice with EAE, labeled
with Cy3 (shown in green) versus wild type mice with EAE labeled with
Cy5 (shown in red). Selected proteins identified by Mass Spectrometry
are indicated with roman indices (see Fig. 5). Proteins were separated
on 24 cm IPG Strip pH 3–10 non-linear.
doi:10.1371/journal.pone.0007624.g004
Figure 5. Statistical evaluation of regulated proteins in CNTF 2/2 mice. 2D DIGE analysis of the average spot volume increase ratio of
proteins shown in Fig. 4. Using the DeCyder’s Biological Variation Analysis module, a paired Student’s t-test yielded a p-value within the 99th
percentile confidence level. Mean value crosses are connected; IS = Internal Standard.
doi:10.1371/journal.pone.0007624.g005
Proteomics in EAE
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injury [47]. As identified in CNTF 2/2 mice, alpha internexin
may present another interesting candidate marker for degenerative
changes in MS, similar to neurofilament proteins (see above).
In summary, our findings underscore the value of proteome
profiling as screening technique for biomarkers determining the
disease stage, but also for the identification of prevailing
pathomechanisms in autoimmune demyelination. In particular,
stage specific EAE models [19] may indicate which molecule bears
the highest level of success as biomarker for disease progression not
only for EAE itself, but possibly also for MS. While proteomics
may help to identify new biomarkers, this technique could also be
beneficial to understand pathophysiological changes or to predict
treatment responses in chronic inflammatory diseases of the CNS
as recently shown for DNA vaccination [18].
Acknowledgments
The skillful technical assistance of Silvia Seubert and Alexandra Bohl is
gratefully acknowledged. We thank Dr Evanthia Mergia, Institute of
Pharmacology, Ruhr-University Bochum, Germany for technical help with
Western Blot analysis and Prof. M. Sendtner, Neurobiology, University
Wu ¨rzburg for continuous support and helpful discussion.
Author Contributions
Conceived and designed the experiments: RAL RG MO. Performed the
experiments: RAL PB SJ ARA OJ. Analyzed the data: RAL PS DHL ARA
OJ MO. Contributed reagents/materials/analysis tools: HT RG MO.
Wrote the paper: RAL RG MO.
References
1. Brex PA, Miszkiel KA, O’Riordan JI, Plant GT, Moseley IF, et al. (2001)
Assessing the risk of early multiple sclerosis in patients with clinically isolated
syndromes: the role of a follow up MRI. J Neurol Neurosurg Psychiatry 70:
390–393.
2. Tintore M, Rovira A, Rio J, Nos C, Grive E, et al. (2006) Baseline MRI predicts
future attacks and disability in clinically isolated syndromes. Neurology 67:
968–972.
3. Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, et al. (2002) A
longitudinal study of abnormalities on MRI and disability from multiple
sclerosis. N Engl J Med 346: 158–164.
4. Bielekova B, Martin R (2004) Development of biomarkers in multiple sclerosis.
Brain 127: 1463–1478.
5. Lutterotti A, Berger T, Reindl M (2007) Biological markers for multiple sclerosis.
Curr Med Chem 14: 1956–1965.
6. Kuhle J, Lindberg RL, Regeniter A, Mehling M, Hoffmann F, et al. (2007)
Antimyelin antibodies in clinically isolated syndromes correlate with inflamma-
tion in MRI and CSF. J Neurol 254: 160–168.
7. Rauer S, Euler B, Reindl M, Berger T (2006) Antimyelin antibodies and the risk
of relapse in patients with a primary demyelinating event. J Neurol Neurosurg
Psychiatry 77: 739–742.
8. Villar LM, Masjuan J, Gonzalez-Porque P, Plaza J, Sadaba MC, et al. (2003)
Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol
53: 222–226.
9. Villar LM, Sadaba MC, Roldan E, Masjuan J, Gonzalez-Porque P, et al. (2005)
Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an
aggressive disease course in MS. J Clin Invest 115: 187–194.
10. Schneider R, Euler B, Rauer S (2007) Intrathecal IgM-synthesis does not
correlate with the risk of relapse in patients with a primary demyelinating event.
Eur J Neurol 14: 907–911.
11. Kroner A, Mehling M, Hemmer B, Rieckmann P, Toyka KV, et al. (2005) A
PD-1 polymorphism is associated with disease progression in multiple sclerosis.
Ann Neurol 58: 50–57.
12. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, et al. (2007) Risk
alleles for multiple sclerosis identified by a genomewide study. N Engl J Med
357: 851–862.
13. Comabella M, Martin R (2007) Genomics in multiple sclerosis–current state and
future directions. J Neuroimmunol 187: 1–8.
14. Fossey SC, Vnencak-Jones CL, Olsen NJ, Sriram S, Garrison G, et al. (2007)
Identification of molecular biomarkers for multiple sclerosis. J Mol Diagn 9:
197–204.
15. Ibrahim SM, Gold R (2005) Genomics, proteomics, metabolomics: what is in a
word for multiple sclerosis? Curr Opin Neurol 18: 231–235.
16. Sturzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A,
et al. (2003) Expression profiling identifies responder and non-responder
phenotypes to interferon-beta in multiple sclerosis. Brain 126: 1419–1429.
17. Balboni I, Chan SM, Kattah M, Tenenbaum JD, Butte AJ, et al. (2006)
Multiplexed protein array platforms for analysis of autoimmune diseases. Annu
Rev Immunol 24: 391–418.
18. Robinson WH, Fontoura P, Lee BJ, de Vegvar HE, Tom J, et al. (2003) Protein
microarrays guide tolerizing DNA vaccine treatment of autoimmune enceph-
alomyelitis. Nat Biotechnol 21: 1033–1039.
19. Gold R, Linington C, Lassmann H (2006) Understanding pathogenesis and
therapy of multiple sclerosis via animal models: 70 years of merits and culprits in
experimental autoimmune encephalomyelitis research. Brain 129: 1953–1971.
20. Herrero-Herranz E, Pardo LA, Gold R, Linker RA (2008) Pattern of axonal
injury in murine myelin oligodendrocyte glycoprotein induced experimental
autoimmune encephalomyelitis: implications for multiple sclerosis. Neurobiol
Dis 30: 162–173.
Figure 6. CNTF deficiency leads to destructive EAE lesions with enhanced apoptosis. EAE lesions in CTNF 2/2 mice (left) are destructive
with vacuolar degeneration (asterisks) and multiple apoptotic cells with pycnotic nuclei (depicted by arrows). These changes are not present in EAE
lesions from wild-type control mice (right side). Representative cervical spinal cord cross sections from a CNTF 2/2 knockout mouse and a wild-type
CNTF +/+ control mouse on day 35 p.i. of MOG-EAE are shown. Bar =50 mm.
doi:10.1371/journal.pone.0007624.g006
Proteomics in EAE
PLoS ONE | www.plosone.org 8 October 2009 | Volume 4 | Issue 10 | e762421. Alt C, Duvefelt K, Franzen B, Yang Y, Engelhardt B (2005) Gene and protein
expression profiling of the microvascular compartment in experimental
autoimmune encephalomyelitis in C57Bl/6 and SJL mice. Brain Pathol 15:
1–16.
22. Ibrahim SM, Mix E, Bottcher T, Koczan D, Gold R, et al. (2001) Gene
expression profiling of the nervous system in murine experimental autoimmune
encephalomyelitis. Brain 124: 1927–1938.
23. Liu T, Donahue KC, Hu J, Kurnellas MP, Grant JE, et al. (2007) Identification
of differentially expressed proteins in experimental autoimmune encephalomy-
elitis (EAE) by proteomic analysis of the spinal cord. J Proteome Res 6:
2565–2575.
24. Duzhak T, Emerson MR, Chakrabarty A, Alterman MA, Levine SM (2003)
Analysis of protein induction in the CNS of SJL mice with experimental allergic
encephalomyelitis by proteomic screening and immunohistochemistry. Cell Mol
Biol (Noisy -le-grand) 49: 723–732.
25. Linker RA, Maurer M, Gaupp S, Martini R, Holtmann B, et al. (2002) CNTF is
a major protective factor in demyelinating CNS disease: a neurotrophic cytokine
as modulator in neuroinflammation. Nat Med 8: 620–624.
26. Masu Y, Wolf E, Holtmann B, Sendtner M, Brem G, et al. (1993) Disruption of
the CNTF gene results in motor neuron degeneration. Nature 365: 27–32.
27. Tastet C, Lescuyer P, Diemer H, Luche S, Van DA, et al. (2003) A versatile
electrophoresis system for the analysis of high- and low-molecular-weight
proteins. Electrophoresis 24: 1787–1794.
28. Steinacker P, Schwarz P, Reim K, Brechlin P, Jahn O, et al. (2005) Unchanged
survival rates of 14-3-3gamma knockout mice after inoculation with pathological
prion protein. Mol Cell Biol 25: 1339–1346.
29. Asif AR, Oellerich M, Amstrong VW, Riemenschneider B, Monod M, et al.
(2006) Proteome of conidial surface associated proteins of Aspergillus fumigatus
reflecting potential vaccine candidates and allergens. J Proteome Res 5:
954–962.
30. Brechlin P, Jahn O, Steinacker P, Cepek L, Kratzin H, et al. (2008)
Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis
(2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease.
Proteomics 8: 4357–4366.
31. Jahn O, Hesse D, Reinelt M, Kratzin HD (2006) Technical innovations for the
automated identification of gel-separated proteins by MALDI-TOF mass
spectrometry. Anal Bioanal Chem 386: 92–103.
32. Werner HB, Kuhlmann K, Shen S, Uecker M, Schardt A, et al. (2007)
Proteolipid protein is required for transport of sirtuin 2 into CNS myelin.
J Neurosci 27: 7717–7730.
33. Schott P, Asif AR, Graf C, Toischer K, Hasenfuss G, et al. (2008) Myocardial
adaptation of energy metabolism to elevated preload depends on calcineurin
activity: a proteomic approach. Basic Res Cardiol 103: 232–243.
34. Mergia E, Russwurm M, Zoidl G, Koesling D (2003) Major occurrence of the
new alpha2beta1 isoform of NO-sensitive guanylyl cyclase in brain. Cell Signal
15: 189–195.
35. Werner P, Pitt D, Raine CS (2001) Multiple sclerosis: altered glutamate
homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann
Neurol 50: 169–180.
36. Kothavale A, Di GD, Somera FP, Smith ME (1995) GFAP mRNA fluctuates in
synchrony with chronic relapsing EAE symptoms in SJL/J mice. Glia 14:
216–224.
37. Norgren N, Sundstrom P, Svenningsson A, Rosengren L, Stigbrand T, et al.
(2004) Neurofilament and glial fibrillary acidic protein in multiple sclerosis.
Neurology 63: 1586–1590.
38. Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, et al. (2003) Quantification
of neurodegeneration by measurement of brain-specific proteins.
J Neuroimmunol 138: 45–48.
39. Liedtke W, Edelmann W, Chiu FC, Kucherlapati R, Raine CS (1998)
Experimental autoimmune encephalomyelitis in mice lacking glial fibrillary
acidic protein is characterized by a more severe clinical course and an infiltrative
central nervous system lesion. Am J Pathol 152: 251–259.
40. Liedtke W, Edelmann W, Bieri PL, Chiu FC, Cowan NJ, et al. (1996) GFAP is
necessary for the integrity of CNS white matter architecture and long-term
maintenance of myelination. Neuron 17: 607–615.
41. Petzold A, Keir G, Green AJ, Giovannoni G, Thompson EJ (2004) An ELISA
for glial fibrillary acidic protein. J Immunol Methods 287: 169–177.
42. Petzold A, Eikelenboom MJ, Gveric D, Keir G, Chapman M, et al. (2002)
Markers for different glial cell responses in multiple sclerosis: clinical and
pathological correlations. Brain 125: 1462–1473.
43. Rejdak K, Eikelenboom MJ, Petzold A, Thompson EJ, Stelmasiak Z, et al.
(2004) CSF nitric oxide metabolites are associated with activity and progression
of multiple sclerosis. Neurology 63: 1439–1445.
44. Giovannoni G (2006) Multiple sclerosis cerebrospinal fluid biomarkers. Dis
Markers 22: 187–196.
45. Werner P, Pitt D, Raine CS (2000) Glutamate excitotoxicity–a mechanism for
axonal damage and oligodendrocyte death in Multiple Sclerosis? J Neural
Transm Suppl: 375–385.
46. Lassmann H, Reindl M, Rauschka H, Berger J, boul-Enein F, et al. (2003) A
new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis
lesions. Brain 126: 1347–1357.
47. Mathey EK, Derfuss T, Storch MK, Williams KR, Hales K, et al. (2007)
Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp
Med 204: 2363–2372.
Proteomics in EAE
PLoS ONE | www.plosone.org 9 October 2009 | Volume 4 | Issue 10 | e7624